Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications

Blood

Volumn 95, Issue 6, 2000, Pages 1942-1949

  Wong, Ivy H N ^b   Ng, Margaret H L ^a   Huang, Dolly P ^b   Lee, Joseph C K ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PROTEIN P15; PROTEIN P16;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CELL; BONE MARROW CELL; CANCER RECURRENCE; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CYTOGENETICS; HUMAN; KARYOTYPE; LEUKEMIA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; RISK ASSESSMENT; SEQUENCE ANALYSIS;

EID: 0034654269     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.6.1942     Document Type: Article

References (52)

1. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993;73:487.
2. Hangaishi A, Ogawa S, Imamura N, et al. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood, 1996;87:4949.
3. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B1. Cancer Res. 1996;56:722.
4. Takeuchi S, Bartram CR, Seriu T, et al. Analysis of a family of cyclin-dependent kinase inhibitors: P15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 1995;86:755.
5. Ogawa S, Hangaishi A, Miyawaki S, et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood. 1995;86:1548.
6. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 1997;89:2500.
7. Wong IHN, Ng MHL, Lee JCK, Lo KW, Chung YF, Huang DP. Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation. Br J Haematol. 1998;103:168.
8. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/ MTS1 in human cancers. Nature Med. 1995;1: 686.
9. Okuda T, Shurtleff SA, Valentine MB, et al. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood. 1995;85:2321.
10. Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997;57:832.
11. Iravani M, Dhat R, Price CM. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene. 1997;15:2609.
12. Sill H, Aguiar RCT, Schmidt H, Hochhaus A, Goldman JM, Cross NCP. Mutational analysis of the p15 and p16 genes in acute leukemias. Br J Haematol. 1996;92:681.
13. Ohnishi H, Kawamura M, Ida K, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood. 1995;86: 1269.
14. Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 1997;89: 4161.
15. Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or p16 gene as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15: 1778.
16. Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res. 1998;58:1245.
17. Herman JG, Civin Cl, Issa JPJ, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactishy; vation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837.
18. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994; 54:6078.
19. Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, P16INK4/MTS1- and p15INK4/ MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994;8:2939.
20. Shilo Y, Yamamoto T, Yamaguchi N. Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci U S A. 1992;89:5206.
21. Vonlanthen, S, Heighway J, Tschan MP, et al. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene. 1998;17:2779.
22. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16(INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 1996;93:13,742.
23. Stone S. Dayananth P, Jiang P, et al. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene. 1995;11:987.
24. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature. 1994;371:257.
25. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood. 1998;92: 574.
26. Cayuela JM, Baruchel A, Orange C, et al. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood. 1996;88: 302.
27. Fukutani H, Naoe T, Ohno R, et al. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia: the Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). Leukemia. 1995;9:588.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821.
29. Mitelman F: ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
30. Wong IHN, Lo YMD, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999; 59:71.
31. Wong IHN, Leung T, Ho S, Lau WY, Chan M, Johnson PJ. Semiquantification of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. Br J Cancer. 1997;76:628.
32. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156.
33. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985.
34. Maloney KW, Rubnitz JE, Cleary ML, et al. Lack of ETV6 (TEL) gene rearrangements or p16ink4A/p15ink4B homozygous gene deletions in infant acute lymphoblastic leukemia. Leukemia. 1997;11:979.
35. Dodge JE, List AF, Futscher BW. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia, Int J Cancer. 1998;78:561.
36. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998; 95:11,891.
37. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999; 59:3853.
38. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86:774.
39. Frickhofen N, Muller E, Sandherr M, et al. Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood. 1997;90:4953.
40. Lo YMD, Wong IHN, Zhang J, Tein MSC, Ng MHL, Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 1999;59:3899.
41. Gronbaek K, Nedergaard T, Andersen MK, et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia. 1998;12:1266.
42. Maesawa C, Tamura G, Nishizuka S, et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 1996;56:3875.
43. Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ. Mechanism of inactivalion of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene. 1995;11:1843.
44. Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995;55:2713.
45. Huschtscha LI, Noble JR, Neumann AA, et al. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 1998;58: 3508.
46. Maloney KW, McGavran L, Odom LF, Hunger SP. Different patterns of homozygous p16INK4A and p15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations. Leukemia. 1998;12:1417.
47. Ohnishi H, Hanada R, Horibe K, et al. Homozygous deletions of p16/MTS1 and p15/MTS2 gene are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood. Leukemia. 1996;10:1104.
48. Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16ink4A and p15ink4B gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood. 1999;93:2380.
49. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler P. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood. 1995;85:2699.
50. Sill H, Goldman JM, Cross NCP. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85:2013.
51. Heyman M, Rasool O, Borgonovo Brandter L, et al. Prognostic importance of p15ink4B and p16ink4A gene inactivation in childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;14: 1512.
52. Momparler RL, Bouchard J, Onetto N, Rivard GE. 5-aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leukemia Res. 1984;8:181.